These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35977045)

  • 1. CD123 Antagonistic Peptides Assembled with Nanomicelles Act as Monotherapeutics to Combat Refractory Acute Myeloid Leukemia.
    Xu S; Zhang M; Fang X; Hu X; Xing H; Yang Y; Meng J; Wen T; Liu J; Wang J; Wang C; Xu H
    ACS Appl Mater Interfaces; 2022 Aug; 14(34):38584-38593. PubMed ID: 35977045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia.
    Xu S; Zhang M; Fang X; Meng J; Xing H; Yan D; Liu J; Yang Y; Wen T; Zhang W; Wang J; Wang C; Xu H
    J Hematol Oncol; 2021 Nov; 14(1):193. PubMed ID: 34774070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.
    Wang M; Wu H; Duan M; Yang Y; Wang G; Che F; Liu B; He W; Li Q; Zhang L
    Life Sci; 2019 Sep; 232():116663. PubMed ID: 31323275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD16
    Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
    Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
    He SZ; Busfield S; Ritchie DS; Hertzberg MS; Durrant S; Lewis ID; Marlton P; McLachlan AJ; Kerridge I; Bradstock KF; Kennedy G; Boyd AW; Yeadon TM; Lopez AF; Ramshaw HS; Iland H; Bamford S; Barnden M; DeWitte M; Basser R; Roberts AW
    Leuk Lymphoma; 2015 May; 56(5):1406-15. PubMed ID: 25248882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
    Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
    [No Abstract]   [Full Text] [Related]  

  • 8. CD123-targeted therapy in acute myeloid leukemia.
    Espinoza-Gutarra MR; Green SD; Zeidner JF; Konig H
    Expert Rev Hematol; 2021 Jun; 14(6):561-576. PubMed ID: 34043467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy.
    Wu H; Zhang L; Zhu Z; Ding C; Chen S; Liu R; Fan H; Chen Y; Li H
    Drug Deliv; 2021 Dec; 28(1):1166-1178. PubMed ID: 34121564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
    Bonnevaux H; Guerif S; Albrecht J; Jouannot E; De Gallier T; Beil C; Lange C; Leuschner WD; Schneider M; Lemoine C; Caron A; Amara C; Barrière C; Siavellis J; Bardet V; Luna E; Agrawal P; Drake DR; Rao E; Wonerow P; Carrez C; Blanc V; Hsu K; Wiederschain D; Fraenkel PG; Virone-Oddos A
    Oncoimmunology; 2021; 10(1):1945803. PubMed ID: 34484869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomicelles co-loading CXCR4 antagonist and doxorubicin combat the refractory acute myeloid leukemia.
    Zhang M; Ge Y; Xu S; Fang X; Meng J; Yu L; Wang C; Liu J; Wen T; Yang Y; Wang C; Xu H
    Pharmacol Res; 2022 Nov; 185():106503. PubMed ID: 36241000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
    J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia.
    Meng J; Ge Y; Xing H; Wei H; Xu S; Liu J; Yan D; Wen T; Wang M; Fang X; Ma L; Yang Y; Wang C; Wang J; Xu H
    Small; 2020 Aug; 16(31):e2001890. PubMed ID: 32608185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
    Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
    Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; Thomas D; Fabri L; Vairo G; Lock RB; Lopez AF; Nash AD
    Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
    Kandeel EZ; Madney Y; Eldin DN; Shafik NF
    Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
    Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
    Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
    Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
    Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
    Kovtun Y; Jones GE; Adams S; Harvey L; Audette CA; Wilhelm A; Bai C; Rui L; Laleau R; Liu F; Ab O; Setiady Y; Yoder NC; Goldmacher VS; Chari RVJ; Pinkas J; Chittenden T
    Blood Adv; 2018 Apr; 2(8):848-858. PubMed ID: 29661755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.